Spotlight Stories

  1. Vor Bio's Transition Into Clinical Trials 4/3/2023

    Vor Bio’s story, for all of its uniqueness, can teach important lessons in many different quarters, involving everything from mundane tactics to dramatic strategies.

  2. U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin 4/3/2023

    Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.

  3. The Neo CEO 3/1/2023

    Lex Rovner founded her company with support from academic scientists and has headed it since it opened for business in 2018. At that time, she had no prior experience as a company founder or as a CEO.

  4. Making The Right Deal For Biohaven 3/1/2023

    Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.

  5. Translating Nobel Prize Winning Science Into Medicine 3/1/2023

    2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.

  6. Scientist-Founders Reshape The Bio Biz 2/1/2023

    Recently, it seems, new scientist-leaders have emerged whose backgrounds and acquired knowledge begin in science but grow to encompass business as well. Mammoth Biosciences is building, and betting, on such a model.

  7. With Fundraising, A Track Record Matters: GeoVax's David Dodd 2/1/2023

    Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.

  8. Why Takeda Is Focusing So Much On Plasma-Derived Therapies 2/1/2023

    Tasked with driving future growth of Takeda’s plasma-derived therapies, Giles Platford, business unit president, shares his approach to partnering, promoting market access, and improving patient experiences.

  9. Verve Therapeutics: How To Build A Gene Editing Biotech 1/3/2023

    Verve Therapeutics’ co-founder and CEO Sekar Kathiresan offers insight into how he launched a gene editing drug company and dosed the first patient in less than four years.

  10. Peter Marks: Prioritizing Better Communication And Faster Product Reviews 1/3/2023

    In an exclusive interview, FDA’s Peter Marks discusses CBER priorities, PDUFA VII funding, and improving the dialogue between regulators and drugmakers.